• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form E filed

    12/23/20 12:15:27 AM ET
    $MGEN
    Medical Specialities
    Health Care
    Get the next $MGEN alert in real time by email
    EDGAR Filing Documents for 9999999995-20-003637
    Home | Latest Filings | Previous Page
    SEC Seal
    SEC Banner
    Search the Next-Generation EDGAR System
    Filing Detail
    • SEC Home »
    • Search the Next-Generation EDGAR System »
    • Company Search »
    • Current Page
    Form EFFECT - Notice of Effectiveness:
    SEC Accession No. 9999999995-20-003637
    Accepted
    2020-12-23 00:15:27
    Documents
    1
    Effectiveness Date
    2020-12-22
    Registration Form
    S-3

    Document Format Files

    Seq Description Document Type Size
    1 primary_doc.html EFFECT  
    1 primary_doc.xml EFFECT 596
      Complete submission text file 9999999995-20-003637.txt   1965
    Mailing Address 6200 LOOKOUT ROAD BOULDER CO 80301
    Business Address 6200 LOOKOUT ROAD BOULDER CO 80301 303-531-5952
    MIRAGEN THERAPEUTICS, INC. (Filer) CIK: 0001590750 (see all company filings)

    IRS No.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
    Type: EFFECT | Act: 33 | File No.: 333-251367 | Film No.: 201409663
    SIC: 8071 Services-Medical Laboratories
    Office of Life Sciences

    Get the next $MGEN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MGEN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MGEN
    SEC Filings

    View All

    SEC Form 8-K filed

    8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)

    1/20/21 8:01:58 AM ET
    $MGEN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed

    SC 13G - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

    1/19/21 4:18:23 PM ET
    $MGEN
    Medical Specialities
    Health Care

    SEC Form 4 filed by Stuart William Marshall

    4 - MIRAGEN THERAPEUTICS, INC. (0001590750) (Issuer)

    1/15/21 7:47:57 PM ET
    $MGEN
    Medical Specialities
    Health Care

    $MGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by L Joseph Turner

    4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

    2/8/21 5:41:03 PM ET
    $MGEN
    Medical Specialities
    Health Care

    SEC Form 4 filed by Evan Peter Harwin

    4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

    2/8/21 5:40:19 PM ET
    $MGEN
    Medical Specialities
    Health Care

    SEC Form 4 filed by S. Jeffrey Hatfield

    4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

    2/8/21 5:40:28 PM ET
    $MGEN
    Medical Specialities
    Health Care

    $MGEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including Expansion of Leadership Team

    Jonathan Violin, Ph.D., M.B.A. appointed President, CEO and director Barrett Katz, M.D., M.B.A. joins Viridian as Chief Medical OfficerViridian is developing VRDN-001 and VRDN-002 for the treatment of thyroid eye diseaseCompany recently licensed exclusive rights from Xencor, Inc. to develop and commercialize therapeutic antibodies targeting IGF-1R incorporating Xtend™ Fc half-life extension technology BOULDER, Colo., Jan. 19, 2021 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotechnology company, today announced its name change to Viridian Therapeutics, Inc. (“Viridian”).   Beginning tomorrow, Viridian will trade on NASDAQ under the ticker symbol "VR

    1/19/21 7:00:00 AM ET
    $MGEN
    Medical Specialities
    Health Care

    miRagen Enters into License Agreement with Xencor for use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease

    Company obtains exclusive rights to develop and commercialize antibody therapeutics targeting insulin-like growth factor-1 receptor (IGF-1R) using Xencor’s Xtend™ half-life extension technology miRagen expects to file an Investigational New Drug (IND) application for VRDN-002, including half-life extension, by the end of 2021 BOULDER, Colo., Dec. 17, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotechnology company, today announced an agreement under which miRagen gains exclusive rights to develop and commercialize therapeutic antibodies targeting IGF-1R incorporating Xtend™ Fc technology from Xencor, Inc. This clinically validated technology p

    12/17/20 7:00:00 AM ET
    $MGEN
    Medical Specialities
    Health Care

    $MGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Miragen Therapeutics, Inc.

    SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

    3/15/21 4:38:22 PM ET
    $MGEN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed

    SC 13G - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

    3/10/21 7:17:41 AM ET
    $MGEN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed

    SC 13G - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

    2/19/21 8:02:11 AM ET
    $MGEN
    Medical Specialities
    Health Care

    $MGEN
    Leadership Updates

    Live Leadership Updates

    View All

    miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including Expansion of Leadership Team

    Jonathan Violin, Ph.D., M.B.A. appointed President, CEO and director Barrett Katz, M.D., M.B.A. joins Viridian as Chief Medical OfficerViridian is developing VRDN-001 and VRDN-002 for the treatment of thyroid eye diseaseCompany recently licensed exclusive rights from Xencor, Inc. to develop and commercialize therapeutic antibodies targeting IGF-1R incorporating Xtend™ Fc half-life extension technology BOULDER, Colo., Jan. 19, 2021 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotechnology company, today announced its name change to Viridian Therapeutics, Inc. (“Viridian”).   Beginning tomorrow, Viridian will trade on NASDAQ under the ticker symbol "VR

    1/19/21 7:00:00 AM ET
    $MGEN
    Medical Specialities
    Health Care